Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT00691717

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension

Sponsor: Alcon Research

Conditions Open-angle Glaucoma Oular Hypertension

Interventions Anecortave Acetate Sterile Suspension, 30 mg/mL Anecortave Acetate Sterile Suspension, 60 mg/mL Anecortave Acetate Sterile Suspension, 75 mg/mL Anecortave Acetate Vehicle

Updated 7 times since 2017 Last updated: Nov 27, 2012 Started: Jun 30, 2008 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Open-angle Glaucoma and Oular Hypertension, this trial is completed. The trial is conducted by Alcon Research and has accumulated 7 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research

Data source: Alcon Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charleston, United States